Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy

収録刊行物

• Lung Cancer

  Lung Cancer 56 383-389, 2007